Trials / Terminated
TerminatedNCT00405561
Study to Evaluate Progression Free Survival in Cancer Patients With Advanced Colorectal Carcinoma With AMT2003
A Prospective, Open, Single-Arm, Multicenter Phase II Clinical Trial to Evaluate the Progression Free Survival and Safety in Patients With Advanced Colorectal Carcinoma Treated With AMT2003
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Auron Healthcare GmbH · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate efficacy and safety of AMT2003 in cancer patients with advanced colorectal carcinoma. The primary endpoint is progression free survival rate at 18 weeks after registration
Detailed description
The study will include patients with advanced colorectal carcinoma that is refractory to standard therapy or for which no effective standard therapy exists. Eligible patients must have had at least second-line chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMT2003 |
Timeline
- Start date
- 2006-10-01
- Primary completion
- 2010-01-01
- Completion
- 2010-01-01
- First posted
- 2006-11-30
- Last updated
- 2013-03-20
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00405561. Inclusion in this directory is not an endorsement.